Second Sight’s second product might lead the company to second place in the market.
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
Promising early data with Sangamo and Pfizer’s haemophilia A gene therapy could set up a battle with Roche and Biomarin.
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
A phase III failure will do nothing to help Supernus’s SPN-812 compete against generic ADHD drugs.
Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.